JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Search

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

22.59 1.44

Overview

Share price change

24h

Current

Min

22.27

Max

22.77

Key metrics

By Trading Economics

Income

202M

274M

Sales

5.4M

284M

P/E

Sector Avg

9.696

67.147

Profit margin

96.33

Employees

796

EBITDA

-21M

26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+43.62% upside

Dividends

By Dow Jones

Next Earnings

6 May 2026

Market Stats

By TradingEconomics

Market Cap

-366M

3.8B

Previous open

21.15

Previous close

22.59

Technical Score

By Trading Central

Confidence

Bullish Evidence

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 Apr 2026, 23:33 UTC

Hot Stocks

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 Apr 2026, 23:24 UTC

Earnings

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 Apr 2026, 23:15 UTC

Major News Events

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 Apr 2026, 22:46 UTC

Earnings

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 Apr 2026, 22:37 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 Apr 2026, 22:15 UTC

Earnings
Major News Events

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 Apr 2026, 23:33 UTC

Market Talk
Major News Events

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 Apr 2026, 23:31 UTC

Earnings

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 Apr 2026, 23:31 UTC

Earnings

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 Apr 2026, 23:30 UTC

Earnings

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 Apr 2026, 23:30 UTC

Earnings

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 Apr 2026, 23:19 UTC

Market Talk
Earnings

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 Apr 2026, 23:09 UTC

Earnings

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 Apr 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 Apr 2026, 23:01 UTC

Major News Events

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 Apr 2026, 23:01 UTC

Major News Events

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 Apr 2026, 23:01 UTC

Major News Events

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 Apr 2026, 23:01 UTC

Major News Events

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 Apr 2026, 23:01 UTC

Major News Events

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 Apr 2026, 22:51 UTC

Earnings

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 Apr 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 Apr 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 Apr 2026, 22:40 UTC

Market Talk
Major News Events

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 Apr 2026, 22:32 UTC

Earnings

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 Apr 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 Apr 2026, 22:22 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 Apr 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 Apr 2026, 22:14 UTC

Earnings

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 Apr 2026, 22:14 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 Apr 2026, 22:07 UTC

Market Talk
Major News Events

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

43.62% upside

12 Months Forecast

Average 31.54 USD  43.62%

High 40 USD

Low 23 USD

Based on 15 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

11

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

14.845 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Neutral Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat